Filing Analysis
Equillium, Inc. held its 2026 Annual Meeting of Stockholders on May 28, 2026, where shareholders approved several key amendments to the Certificate of Incorporation, most notably a reverse stock split and a significant increase in authorized shares.
🚩 Red Flags
- Approval of a reverse stock split (1-for-2 to 1-for-20) is a classic red flag for micro-cap companies, often used to artificially inflate share price to avoid Nasdaq delisting.
- Doubling the authorized share count (from 200M to 400M) creates significant potential for future shareholder dilution.
- Multiple high-impact items (reverse split and share authorization increase) approved in a single meeting.
📋 Key Facts
- Stockholders approved a reverse stock split with a ratio range of 1-for-2 to 1-for-20, to be determined by the Board of Directors.
- The authorized number of common stock shares was increased from 200,000,000 to 400,000,000 shares.
- Crowe LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- The Board of Directors was reduced from seven members to six following the expiration of Peter Colabuono's term.
- Charles McDermott and Bruce Steel were elected as Class II directors.
Equillium, Inc. announced its financial results for the first quarter ended March 31, 2026. The disclosure was made via a press release furnished as an exhibit to the 8-K filing.
📋 Key Facts
- The company reported financial results for the fiscal quarter ended March 31, 2026.
- The report was filed on May 13, 2026, under Item 2.02 (Results of Operations and Financial Condition).
- The financial information was furnished and not deemed 'filed' for purposes of Section 18 of the Exchange Act.
- The filing includes Exhibit 99.1, which is the press release containing the financial details.
Equillium, Inc. reported its financial results for the fourth quarter and full year ended December 31, 2025. The information was furnished via a press release and does not include any immediate material changes to corporate structure or auditor status.
📋 Key Facts
- Report date: March 25, 2026
- Financial period covered: Fourth quarter and full year ended December 31, 2025
- The filing was made under Item 2.02 (Results of Operations and Financial Condition)
- The report was signed by Bruce D. Steel, Chief Executive Officer
Equillium, Inc. entered into a securities purchase agreement for a private placement (PIPE) with RA Capital Healthcare Fund, L.P., raising approximately $35.0 million in gross proceeds. The transaction involves the sale of common stock and pre-funded warrants to fund the development of its EQ504 program and for general working capital.
🚩 Red Flags
- Substantial potential dilution from the issuance of over 17.6 million shares via pre-funded warrants.
- The securities are being sold in an unregistered private placement, bypassing standard public offering scrutiny.
📋 Key Facts
- Total gross proceeds of approximately $35.0 million from RA Capital Healthcare Fund, L.P.
- Issuance of 1,179,508 shares of common stock at $1.854 per share.
- Issuance of pre-funded warrants to purchase up to 17,698,593 shares at $1.8539 per warrant share.
- The purchase price was based on the five-day average closing price prior to the agreement.
- The company is required to file a resale registration statement within 30 days of closing.
- Closing is anticipated on or about March 13, 2026.